DexCom (DXCM) Peer Comparison
$89.80
$0.84
(0.94%)
As on 27-Aug-2026 10:37EDT
Market cap
$34,845 Mln
Revenue (TTM)
$4,969 Mln
P/E Ratio
36.5
P/B Ratio
13.3
Div. Yield
0 %
Edit
| DexCom (DXCM) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Intuitive Surgical (ISRG) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
34,845 | 232,035 | 201,832 | 151,782 | 135,719 |
Revenue ($ Mln) |
4,969 | 46,336 | 46,585 | 25,107 | 11,034 |
Net Profit ($ Mln) |
999.70 | 6,978.00 | 5,425.00 | 4,004.00 | 3,138.80 |
Net Margin (%) |
20.12 | 15.06 | 11.65 | 15.95 | 28.45 |
RoE (%) |
37.25 | 13.12 | 10.51 | 7.62 | 17.34 |
Price to Earnings |
36.50 | 33.01 | 36.91 | 37.75 | 42.90 |
Price-To-Book |
13.29 | 4.31 | 3.86 | 2.83 | 7.73 |
Income Statement ($ Mln)
| DexCom (DXCM) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Intuitive Surgical (ISRG) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
4,969.20 | 46,336.00 | 46,585.00 | 25,107.00 | 11,034.40 |
|
Cost of Revenue
|
1,864.80 | 27,629.00 | 20,123.00 | 10,416.00 | 3,676.80 |
|
Gross Profit
|
2,801.90 | 16,778.00 | 24,607.00 | 14,970.00 | 6,642.30 |
|
Operating Expenses
|
1,965.30 | 10,515.00 | 18,557.00 | 9,564.00 | 3,906.40 |
|
Operating Profit (EBIT)
|
1,139.10 | 8,195.00 | 7,932.00 | 5,127.00 | 3,451.20 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
1,280.00 | 7,609.00 | 7,511.00 | 4,762.00 | 3,805.80 |
|
Provision for Tax
|
280.30 | 597.00 | 2,086.00 | 758.00 | 647.90 |
|
Profit after Tax (Net Income)
|
999.70 | 6,978.00 | 5,425.00 | 4,004.00 | 3,138.80 |
|
Minority Interest
|
0.00 | -21.00 | 0.00 | 0.00 | -19.10 |
|
Consolidated Profit
|
0.00 | 3,580.00 | 3,420.00 | 2,105.00 | 0.00 |
Liabilities ($ Mln)
| DexCom (DXCM) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Intuitive Surgical (ISRG) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
2,621.40 | 52,679.00 | 51,110.00 | 52,581.00 | 18,168.40 |
|
Minority Interest
|
0.00 | -21.00 | 0.00 | 0.00 | -19.10 |
|
Non-Current Liabilities
|
1,476.20 | 45,298.00 | 39,639.00 | 31,681.00 | 656.00 |
|
Current Liabilities
|
2,357.70 | 15,069.00 | 17,814.00 | 8,105.00 | 1,922.90 |
|
Total Liabilities
|
6,339.90 | 110,343.00 | 86,713.00 | 83,464.00 | 20,631.20 |
Assets ($ Mln)
| DexCom (DXCM) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Intuitive Surgical (ISRG) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
2,368.70 | 89,809.00 | 84,698.00 | 78,986.00 | 11,333.90 |
|
Current Assets
|
4,086.60 | 23,365.00 | 24,517.00 | 13,381.00 | 9,542.70 |
|
Total Assets
|
6,339.90 | 110,343.00 | 86,713.00 | 83,464.00 | 20,631.20 |
|
Total Debt*
|
1,398.40 | 42,549.00 | 32,608.00 | 26,558.00 | 0.00 |
|
Net Current Assets
|
1,728.90 | 8,296.00 | 0.00 | 5,276.00 | 7,619.80 |
Cashflow ($ Mln)
| DexCom (DXCM) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Intuitive Surgical (ISRG) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
1,440.70 | 7,818.00 | 9,566.00 | 6,416.00 | 3,030.50 |
|
Cash Flow from Investing Activities
|
536.00 | -4,047.00 | -2,422.00 | -1,196.00 | 665.80 |
|
Cash from Financing Activities
|
-1,686.40 | 1,801.00 | -6,309.00 | -2,961.00 | -2,364.10 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| DexCom (DXCM) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Intuitive Surgical (ISRG) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
18.95 | 7.69 | 10.03 | 5.25 | 16.46 |
|
ROE (%)
|
37.25 | 13.12 | 10.51 | 7.62 | 17.34 |
|
ROA (%)
|
10.28 | 5.76 | 4.69 | 4.24 | 14.06 |
|
EBIT Margin (%)
|
26.06 | 18.62 | 13.35 | 20.13 | 33.76 |
|
Net Margin (%)
|
20.12 | 15.06 | 11.65 | 15.95 | 28.45 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| DexCom (DXCM) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Intuitive Surgical (ISRG) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
15.54 | 7.23 | 8.06 | 4.56 | 20.66 |
|
EBIT Growth (%)
|
61.25 | 1.20 | -26.60 | 15.73 | 24.96 |
|
Net Profit Growth (%)
|
74.93 | 5.98 | -61.19 | 17.32 | 20.37 |
|
EPS Growth (%)
|
79.21 | 7.77 | -61.19 | 20.09 | 21.65 |
|
Book Value Growth (%)
|
6.14 | 6.26 | 1.54 | 2.10 | 3.40 |
Valuation Ratios
| DexCom (DXCM) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Intuitive Surgical (ISRG) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
31.66 | 32.43 | 33.55 | 45.04 | 71.47 |
|
Price / Book Value
|
9.64 | 4.09 | 4.20 | 3.10 | 11.45 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
19.04 | 21.61 | 19.48 | 25.42 | 49.76 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| DexCom (DXCM) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Intuitive Surgical (ISRG) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.47 | 0.74 | 0.00 | 0.48 | 0.00 |
|
Short term debt to equity ratio
|
0.01 | 0.06 | 0.06 | 0.03 | 0.00 |
|
Current Ratio
|
1.73 | 1.55 | 1.38 | 1.65 | 4.96 |
|
Quick Ratio
|
1.43 | 1.18 | 0.97 | 1.25 | 3.91 |
|
Interest Coverage
|
86.33 | 6.19 | 12.79 | 62.05 | -- |
Operating Efficiency Ratios
| DexCom (DXCM) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Intuitive Surgical (ISRG) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
25.82 | 20.40 | 18.46 | 15.79 | 16.08 |
|
Asset Turnover
|
0.51 | 0.38 | 0.40 | 0.27 | 0.49 |
|
Receivable days
|
91.02 | 82.76 | 61.20 | 61.72 | 54.16 |
|
Inventory Days
|
115.04 | 68.39 | 117.44 | 91.69 | 177.54 |
|
Payable days
|
67.71 | 44.06 | 78.11 | 68.44 | 23.93 |
|
Cash Conversion Cycle
|
138.35 | 107.10 | 100.53 | 84.97 | 207.78 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
